0001493152-21-001815.txt : 20210126 0001493152-21-001815.hdr.sgml : 20210126 20210126163513 ACCESSION NUMBER: 0001493152-21-001815 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210121 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20210126 DATE AS OF CHANGE: 20210126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immune Therapeutics, Inc. CENTRAL INDEX KEY: 0001559356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 593226705 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54933 FILM NUMBER: 21554542 BUSINESS ADDRESS: STREET 1: 2431 ALOMA AVE #124 CITY: WINTER PARK STATE: FL ZIP: 32792 BUSINESS PHONE: (888) 613-8802 MAIL ADDRESS: STREET 1: 2431 ALOMA AVE #124 CITY: WINTER PARK STATE: FL ZIP: 32792 FORMER COMPANY: FORMER CONFORMED NAME: TNI BIOTECH, INC. DATE OF NAME CHANGE: 20121001 8-K 1 form8-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

January 21, 2021

Date of Report (Date of earliest event reported)

 

Immune Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Florida   000-54933   59-3226705
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.

 

2431 Aloma Ave, Suite 124, Winter Park, FL   32792
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code 888-613-8802

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of exchange on which registered
Common stock $0.0001 per share   IMUN   OTC Markets

 

Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

ITEM 5.02: DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

 

On January 21, 2021, Michael Sander notified the Board of Directors of Immune Therapeutics, Inc. (the “Company”) of his resignation as a director of the Company, effective on January 21, 2021, to pursue other interests. Mr. Sander served as director from November 2019.

 

Board Chair Dr. Roscoe M. Moore, Jr. stated that “the Board and shareholders of Immune Therapeutics, Inc. wish to thank Michael for his dedicated service to the Company. During his tenure, Michael added strong insights and direction to the Company. We wish him well in his future endeavors”.

 

Mr. Sander’s resignation was not the result of any dispute or disagreement with the Company or the Company’s Board of Directors on any matter relating to operations, policies or practices of the Company.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMMUNE THERAPEUTICS, INC.
     
Date: January 26, 2021 By: /s/ Kevin J. Phelps
    Kevin J. Phelps, Chief Executive Officer, Director